相关实验视频
Updated: Jul 16, 2026

09:53
In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
16.5K
一种新型的SATB1抗体,用于对莱什马尼亚感染的免疫反应
Diksha Jawale1, Shailza Singh1
1Systems Medicine Laboratory, BRIC-National Centre for Cell Science, NCCS Complex, Ganeshkhind, SPPU Campus, Pune, 411007, India.
Microbial pathogenesis
|November 23, 2025
概括
新型类疗法对皮肤莱什曼病 (CL) 有前途. 研究人员将特别的AT丰富结合蛋白-1 (SATB1) 确定为目标,开发一种可以恢复免疫平衡并有效缓解感染的.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 皮肤莱什曼病 (CL) 是一种具有有限治疗选择的传染病.
- 特别的AT丰富结合蛋白-1 (SATB1) 在CL期间起着调节炎症反应的作用.
- SATB1转移到细胞核驱动了促炎性细胞因子的产生.
研究的目的:
- 确定SATB1作为一种新型的免疫疗法目标,用于CL.
- 开发基于的疗法来破坏SATB1功能并恢复免疫恒常性.
主要方法:
- 基于机器学习的体设计以准SATB1的核定位信号 (NLS).
- 结构预测,图案识别和类库选.
- 在体外和体外对候选物的实验验证.
主要成果:
- 确定了三种具有高结合亲和力的候选物 (P1,P2,P3).
- P3在缓解CL感染方面表现出显著的有效性.
- 在体外和体外模型中,P3成功地恢复了免疫平衡.
结论:
- SATB1是皮肤雷什曼病的可行的免疫治疗点.
- 基于的治疗方法,以P3为例,为治疗CL提供了一个有希望的策略.
- 这种方法对其他免疫相关疾病有潜力.
更多相关视频
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
12.3K
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.5K
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...